A review evaluates the value of several emerging biomarkers for the early detection of lung cancer, covering genetic, epigenetic, transcriptomic, and proteomic signatures in tissue, blood, saliva, and urine. The review notes that low-dose CT screening can reduce mortality by 20% to 24%, but has a high false-positive rate; more than 70% of lung cancer cases are diagnosed at an advanced stage, and early detection can improve survival rates for patients with localized disease while reducing the burden of surgery and subsequent treatment.
Source:BIOENGINEER.ORG · Read the original
Leave a Reply